osimertinib EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Adjuvant osimertinib targeted therapy
erlotinib + ramucirumab EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Metastatic First line erlotinib, +1 more drug targeted therapy
dacomitinib EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Metastatic First line dacomitinib targeted therapy
gefitinib EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Metastatic First line gefitinib targeted therapy
osimertinib EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Metastatic First line osimertinib targeted therapy
afatinib EGFR Codon 719 Missense, +4 more biomarkers Non-Small Cell Lung Carcinoma Metastatic First line afatinib targeted therapy
erlotinib EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Metastatic First line, +2 more contexts erlotinib targeted therapy
afatinib EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Advanced, +1 more state First line afatinib targeted therapy
afatinib + cetuximab EGFR A763_Y764insFQEA, +6 more biomarkers Non-Small Cell Lung Carcinoma Advanced, +1 more state Subsequent line afatinib, +1 more drug targeted therapy
bevacizumab + erlotinib EGFR Exon 19 Deletion, +1 more biomarker Non-Squamous Non-Small Cell Lung Carcinoma Advanced, +1 more state First line bevacizumab, +1 more drug targeted therapy
dacomitinib EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Advanced, +1 more state First line dacomitinib targeted therapy
erlotinib EGFR Exon 19 Deletion, +1 more biomarker Non-Small Cell Lung Carcinoma Advanced, +1 more state First line erlotinib targeted therapy